<i>miR-129-2</i> mediates down-regulation of progesterone receptor in response to progesterone in breast cancer cells

Godbole, Mukul; Chandrani, Pratik; Gardi, Nilesh; Dhamne, Hemant; Patel, Kuldeep; Yadav, Neelima; Gupta, Sudeep; Badwe, Rajendra; Dutt, Amit

doi:10.1080/15384047.2017.1373216

Cited by 19 publications

(22 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this combined evidence warrants further validation, it suggests that this miRNA might play a role in the initiation of breast cancer and could be used as a predictive cancer biomarker. MiR-129-2, that targets the Progesterone Receptor (PR) gene, has been described as upregulated in patients with low PR expression levels (PR-) [86]. This target suppression, is compatible with our findings, showing the up-regulation of miR-129-2 in the TNBC cases when compared to the non-TNBC cases.…”

Section: Discussionsupporting

confidence: 91%

Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients

et al. 2019

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC), a clinically aggressive breast cancer subtype, affects 15–35% of women from Latin America. Using an approach of direct integration of copy number and global miRNA profiling data, performed simultaneously in the same tumor specimens, we identified a panel of 17 miRNAs specifically associated with TNBC of ancestrally characterized patients from Latin America, Brazil. This panel was differentially expressed between the TNBC and non-TNBC subtypes studied (p ≤ 0.05, FDR ≤ 0.25), with their expression levels concordant with the patterns of copy number alterations (CNAs), present mostly frequent at 8q21.3-q24.3, 3q24-29, 6p25.3-p12.2, 1q21.1-q44, 5q11.1-q22.1, 11p13-p11.2, 13q12.11-q14.3, 17q24.2-q25.3 and Xp22.33-p11.21. The combined 17 miRNAs presented a high power (AUC = 0.953 (0.78–0.99);95% CI) in discriminating between the TNBC and non-TNBC subtypes of the patients studied. In addition, the expression of 14 and 15 of the 17miRNAs was significantly associated with tumor subtype when adjusted for tumor stage and grade, respectively. In conclusion, the panel of miRNAs identified demonstrated the impact of CNAs in miRNA expression levels and identified miRNA target genes potentially affected by both CNAs and miRNA deregulation. These targets, involved in critical signaling pathways and biological functions associated specifically with the TNBC transcriptome of Latina patients, can provide biological insights into the observed differences in the TNBC clinical outcome among racial/ethnic groups, taking into consideration their genetic ancestry.

show abstract

Section: Discussionsupporting

confidence: 91%

Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The response to hormonal therapy is affected by the progesterone receptor (PR)-status of patients with breast cancer. The overexpression of miR-129-2 stimulated the effect of progesterone treatment by downregulating PR, and the inhibition of miR-129-2 repealed its interaction with PR in breast cancer cells (43). To the best of our knowledge, there have been no specific experimental studies on luminal A and B breast cancer; however, clinically, the expression of miR-129 in the serum of patients with breast cancer is lower than that of healthy individuals (44,45).…”

Section: Lung Cancermentioning

confidence: 99%

Role of microRNA‑129 in cancer and non‑cancerous diseases (Review)

2021

View full text Add to dashboard Cite

An increasing number of studies indicate that microRNAs (miRNAs/miRs) are involved in diverse biological signaling pathways and play important roles in the progression of various diseases, including both oncological and non-oncological diseases. These small non-coding RNAs can block translation, resulting in a low expression level of target genes. miR-129 is an miRNA that has been the focus of considerable research in recent years. A growing body of evidence shows that the miR-129 family not only functions in cancer, including osteosarcoma, nasopharyngeal carcinoma, and ovarian, prostate, lung, breast and colon cancer, but also in non-cancerous diseases, including heart failure (HF), epilepsy, Alzheimer's disease (AD), obesity, diabetes and intervertebral disc degeneration (IVDD). It is therefore necessary to summarize current research progress on the role of miR-129 in different diseases. The present review includes an updated summary of the mechanisms of the miR-129 family in oncological and non-oncological diseases. To the best of our knowledge, this is the first review focusing on the role of miR-129 in non-cancerous diseases such as obesity, HF, epilepsy, diabetes, IVDD and AD. Contents 1. Introduction 2. Role of miR-129 in oncological phenotypes 3. Role of miR-129 in non-oncological phenotypes 4. Conclusion

show abstract

“…involved in these processes including TGFβ, COF1, EGFR, VEGF and cyclin D1 (17)(18)(19)(20). Although the role of P4 over the expression of miRNAs in GBMs remains to be elucidated, it is known that in breast cancer, P4 regulates the expression of miRNAs with tumor suppressor or oncogenic action, via the classic PR (21)(22)(23)(24)(25)(26)(27)(28)(29)(30). The present study characterized the expression profile of P4-regulated miRNAs in the U-251MG cell line, derived from a human GBM and the biological processes that could be regulated by the differentially expressed (DE) miRNAs.…”

Section: Expression Analysis Of Progesterone-regulated Mirnas In Cells Derived From Human Glioblastomamentioning

confidence: 93%

Expression analysis of progesterone‑regulated miRNAs in cells derived from human glioblastoma

et al. 2021

View full text Add to dashboard Cite

Glioblastomas (GBMs) are the most frequent and malignant type of brain tumor. It has been reported that progesterone (P4) regulates the progression of GBMs by modifying the expression of genes that promote cell proliferation, migration and invasion; however, it is not fully understood how these processes are regulated. It is possible that P4 mediates some of these effects through changes in the microRNA (miRNA) expression profile in GBM cells. The present study investigated the effects of P4 on miRNAs expression profile in U-251MG cells derived from a human GBM. U-251MG cells were treated for 6 h with P4, RU486 (an antagonist of the intracellular progesterone receptor), the combined treatment (P4+RU486) and cyclodextrin (vehicle) and then a miRNA microarray analysis conducted. The expression analysis revealed a set of 190 miRNAs with differential expression in the treatments of P4, RU486 and P4+RU486 in respect to the vehicle and P4 in respect to P4+RU486, of which only 16 were exclusively regulated by P4. The possible mRNA targets of the miRNAs regulated by P4 could participate in the regulation of proliferation, cell cycle progression and cell migration of GBMs. The present study provided insight for understanding epigenetic modifications regulated by sex hormones involved in GBM progression, and for identifying potential therapeutic strategies for these brain tumors.

show abstract

miR-129-2 mediates down-regulation of progesterone receptor in response to progesterone in breast cancer cells

Cited by 19 publications

References 16 publications

Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients

Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients

Role of microRNA‑129 in cancer and non‑cancerous diseases (Review)

Expression analysis of progesterone‑regulated miRNAs in cells derived from human glioblastoma

Contact Info

Product

Resources

About